OncoLink Cancer Treatment and Resources
OncoLink Cancer Treatment and Resources

D’Amico Risk Categories

Last Modified: June 29, 2008

Question

Dear OncoLink "Ask The Experts,"

Can you describe the D'Amico risk categories and how they relate to prognosis ?

Answer

Richard Whittington, MD, Associate Professor of Radiation Oncology at the University of Pennsylvania School of Medicine, responds:

Dr. Anthony D'Amico has shown that it is possible to estimate the biologic aggressiveness of prostate cancers by grouping them into different risk categories, which in turn reflect the risk of cancer growth and spread. When an urologist does a prostate biopsy, he systematically samples the gland from 6 to 12 – and sometimes up to 24 – different areas. The number of involved areas out of the total number sampled is a term called “percent positive biopsies (or cores)”, and indicates how much of the prostate gland is involved with cancer. For example, Dr. D’Amico has found that a tumor that only involves a small percentage of cores can be classified as low risk, whereas a high percentage of positive cores portends a worse prognosis.

Below is the overall risk stratification of this system:

Low risk:
PSA < 10ng/ml and Gleason < 6 and
The percentage of involved cores is < 50% or
Intermediate risk with only 1 positive core

Intermediate risk:
Gleason score of 7 or PSA of 10-20
Low risk with > 50% of positive cores or
High risk and only 1 positive core

High risk:
Gleason > 8 or PSA > 20 and more than 1 positive core
Or intermediate risk and more than 50% positive cores

When there is a conflict in the Gleason score and PSA risk group, the worse factor wins and determines the risk category assignment. For example, a patient with a low Gleason Score of 6 combined with a PSA of 25 ng/ml is considered high risk. The exception to this would be, say, if there is only one positive core out of all of the ones sampled, in which case the risk category goes down to intermediate risk.

OncoLink I wish u knew...

Dr. Rebbeck talks about the role of cancer biology and genetics in cancer research and applying that to clinical care. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy

Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews


Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement

OncoLink Cancer Resources RSS What's New RSS